ClinicalTrials.gg
RecruitingNCT07425782Updated Aug 6, 2026

Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

A Phase 2 interventional study of Ara-C Group and VEN/AZA condsolidation in Acute Myeloid Leukemia, Consolidation Therapy and Venentoclax, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-06.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University — 30 open to participants now, 34 under way, 6 of them phase 3. Leukemia, Myeloid, Acute · The First Affiliated Hospital of Soochow University.

Planned enrollment
4th of 51
216 · median 50
Started
2026
with 10 others
Phase 2
19 of 57
12 open now
Primary completion
2028-11
later than 26 of 33 live
Registered
48th of 57
by date

Among the 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University, this one is the 4th largest by planned enrollment of the 51 interventional ones that give a count, is one of 11 that started in 2026, is one of 19 in phase 2, reaches primary completion later than 26 of the 33 other live ones, and was the 48th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

30 of the 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Leukemia, Myeloid, Acute by The First Affiliated Hospital of Soochow University, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid leukemia (AML) who have achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) after induction therapy with venetoclax and azacitidine and are planned for transplantation.

The main questions it aims to answer are:

Does consolidation therapy with a venetoclax-containing regimen lead to superior clinical outcomes compared to conventional chemotherapy in this specific patient population? What is the comparative safety profile of the venetoclax-containing consolidation regimen versus conventional chemotherapy in these patients? Participants will be randomly assigned to receive either the venetoclax-based consolidation therapy or the conventional consolidation chemotherapy before undergoing transplantation.

Read the detailed description

Background and Rationale:Current AML frontline therapy is shifting from intensive chemotherapy toward precision-based approaches. Venetoclax combined with hypomethylating agents (e.g., azacitidine) has become the standard of care for older or chemotherapy-ineligible patients and has shown comparable efficacy and improved safety in younger, fit patients compared with intensive chemotherapy.Pre-transplant consolidation remains a critical phase for reducing relapse risk; however, conventional cytarabine-based regimens are associated with high relapse rates. To date, no prospective studies have investigated venetoclax-based consolidation in AML. This trial aims to address this gap and provide evidence to guide post-remission therapy.

Study Design and Interventions:Eligible patients (aged ≥18 years) with newly diagnosed high-risk AML who achieved CR/CRi after 1-2 cycles of venetoclax plus azacitidine induction will be randomized 1:1 to:Experimental arm: Venetoclax-based consolidation regimen (per protocol);Comparator arm: Conventional intermediate-dose cytarabine consolidation (per protocol).All patients will proceed to allo-HSCT after 1-2 consolidation cycles.

Endpoints:Primary: Leukemia-free survival (LFS). Key Secondary: MRD-negative rate before transplantation, overall survival (OS), cumulative incidence of relapse (CIR), non-relapse mortality (NRM), and safety profile.

Significance:This study will provide high-level evidence to guide consolidation strategies for high-risk AML in the venetoclax era, with the goal of improving transplant outcomes and long-term survival.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Consolidation Therapy
  • Venentoclax
  • High Risk
  • Hematopoietic Stem Cell Transplant (HSCT)

Keywords

  • Acute Myeloid Leukemia
  • Consolidation Therapy
  • Venentoclax
  • Allogenice Hematopoietic Stem Cell Transplantation
  • High risk
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of AML confirmed by bone marrow morphology, flow cytometry, and molecular genetics, meeting WHO 2022 classification criteria;
  • Age ≥ 18 years;
  • Classified as high-risk according to the European LeukemiaNet (ELN) prognostic risk stratification for AML, including AML with myelodysplasia-related changes (AML-MRC) and therapy-related acute myeloid leukemia (t-AML);
  • Achieved CR or CRi after ≤ 2 cycles of VA induction chemotherapy;
  • Availability of a suitable donor, with plans to undergo hematopoietic stem cell transplantation (allo-HSCT);
  • (ECOG) performance status score of 0 to 2;
  • ≥ 50 mL/min (calculated using the Cockcroft-Gault formula); (AST) and alanine aminotransferase (ALT) ≤ 3 times the (ULN), total ≤ 2 times ULN; (LVEF) ≥ 50% as shown by echocardiography (ECHO); expected survival > 8 weeks;
  • Voluntarily signed the form and can understand and comply with study requirements.

Exclusion criteria

Exclusion Criteria:

  • Presence of clinically active cardiovascular disease, such as uncontrolled ventricular arrhythmia, uncontrolled hypertension, congestive heart failure, cardiac disease classified as Class 3 or 4 according to the (NYHA) Functional Classification, or a history of myocardial infarction within 3 months prior to screening;
  • Active central nervous system leukemia (CNSL) or extramedullary infiltration of leukemia;
  • Other serious diseases that may limit the patient's participation in this trial (e.g., severe infection, renal failure);
  • Known (HIV) infection or uncontrolled severe viral hepatitis;
  • Pregnant or breastfeeding women;
  • Inability to understand, comply with the study protocol, or sign the form;
  • Any other conditions deemed by the investigator as unsuitable for participation in this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
216 participants (estimated)

Study arms

  • Active comparator
    Ara-C Consolidation Arm

    AraC (Cytarabine) 1-2 g/m², administered intravenously every 12 hours on days 1-3, may be combined with anthracycline/anthraquinone agents. After completing 1-2 cycles of consolidation therapy, the patient proceeds to allogeneic hematopoietic stem cell transplantation (allo-HSCT).

    Drug: Ara-C Group

  • Experimental
    VA Consolidation Chemotherapy Arm

    VEN: 400 mg, orally, days 1-28 (Venetoclax dosage must be adjusted per prescribing information/guidelines based on concomitant use of CYP3A4 inhibitors); AZA: 75 mg/m²/day, subcutaneously, days 1-7; Proceed to allogeneic hematopoietic stem cell transplantation (allo-HSCT) after completing 1-2 cycles of consolidation therapy.

    Drug: VEN/AZA condsolidation

Interventions

  • DrugCytarabineStudies of CytarabineCytarabine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ara-C 1-2 g/m², every 12 hours, intravenous infusion, days 1-3; may be combined with anthracyclines/anthraquinones, followed by allo-HSCT after consolidation within 2 cycles.

  • DrugVEN/AZA condsolidation

    Venetoclax 400 mg, orally, days 1-28 (the dose of Venetoclax should be adjusted according to the drug dosage instructions/guidelines when combined with CYP3A4 inhibitors); AZA: Azacitidine 75 mg/m² per day, subcutaneous injection, days 1-7. Patients will proceed to allo-HSCT after consolidation within 2 cycles.

06

What researchers measure

Primary outcomes

  1. Leukemia free survival

    Time from date of achieving complete remission until date of first documented hematologic relapse, extramedullary relapse, or death from any cause, whichever occurs first.

    Time frame: From date of complete remission until the date of first documented relapse or date of death from any cause, whichever came first, assessed up to 2 years.

Secondary outcomes

  1. Pretransplantation MRD negative rate

    Proportion of patients who achieve minimal residual disease (MRD) negativity prior to hematopoietic stem cell transplantation, as assessed by multicolor flow cytometry, measured from bone marrow samples.

    Time frame: From the end of the last consolidation therapy to the initiation of conditioning regimen for allogeneic hematopoietic stem cell transplantation, within approximately 1 month.

  2. Overall survival

    From the first day of randomization to the date of death from any cause

    Time frame: From the first day of randomization to the date of death, assesed up to 2 years.

  3. Cumulative relapse rate

    From the date of achieving remission to the date of hematologic relapse.

    Time frame: From date of achieving remission to the date of death from any cause, assessed up to 2 years.

  4. Non-relapse mortality

    The proportion of patients who died from causes unrelated to disease relapse/progression after achieving remission or receiving an intervention

    Time frame: From date of randomization until date of death without prior relapse or disease progression, assessed up to 2 years.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2028, 33 months after the start.

Of 385 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 107. This study's planned 33 months is below that.

Counting every sponsor, half of 442 studies reached it within 60 months; a quarter within 38 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 23, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Nov 26, 2028
CompletionEst.
Nov 26, 2028
Last update
Aug 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07425782
Responsible party
CHEN Jia (Chief Physician of Hematology. Clinical Professor. Principal Investigator, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Feb 23, 2026
Start date
Feb 1, 2026
Primary completion
Nov 26, 2028 (estimated)
Completion
Nov 26, 2028 (estimated)
Last update
Aug 6, 2026

Study contacts

Qi Qu
Contact
quqimedsz@163.com
+86 051267976801

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion